Sandra Osborne: To ask the Chancellor of the Duchy of Lancaster what assessment he has made of the implications of the Prime Ministers Strategy Unit report Getting On Getting Ahead for his Departments policy on social mobility. 
Significantly, the paper identifies the need to support people from childhood right up until they are on the job ladder and beyond. Supporting families and communities is highlighted as an important context throughout the analysis.
James Brokenshire: To ask the Secretary of State for Health what the cost of treating patients with a primary or secondary diagnosis of excessive alcohol consumption was in each of the last 10 years. 
Dawn Primarolo: The International Classification of Diseases does not include a diagnosis specifically related to excessive alcohol consumption. A 2008 paper by the Department The cost of alcohol harm to the NHS in England: An update to the Cabinet Office (2003) study estimated the 2006-07 cost of hospital admissions where a primary or secondary diagnosis is wholly attributable to alcohol at £183 million in 2008-9 prices. A copy of this paper has been placed in the Library. Those diagnoses defined as wholly attributed to alcohol were:
Alcoholic cardiomyopathy (142.6)
Alcoholic gastritis (K29.2)
Alcoholic myopathy (G72.1)
Alcoholic polyneuropathy (G62.1)
Alcohol-induced pseudo-Cushing's syndrome (E24.4)
Degeneration of nervous system due to alcohol (G31.2)
Mental and behavioural disorders due to use of alcohol (F10)
Accidental poisoning by and exposure to alcohol (X45)
Ethanol poisoning (T51.0)
Methanol poisoning (T51.1)
Toxic effect of alcohol, unspecified (T51.9)
Chronic pancreatitis (alcohol induced) (K86.0)
A Cabinet Office (2003) study Alcohol misuse: How much does it cost? estimated the cost of hospital admissions in 2000-01 at £126 million in 2001 prices. This used a different methodology to the Department's reports and so the estimates are not directly comparable.
Mr. Evennett: To ask the Secretary of State for Health how many people were registered as carers in (a) Bexleyheath and Crayford constituency and (b) the London Borough of Bexley in each of the last five years. 
Dawn Primarolo: Every primary care trust (PCT) in England is now offering chlamydia screening through the National Chlamydia Screening Programme (NCSP). Opportunistic screening is offered to all sexually active women and men, aged under 25 years, in a variety of health and non-health care settings. The Department has made increasing screening volumes and reducing chlamydia prevalence a priority for the national health service and it is included as a tier two indicator in the operating framework for 2008-09 to 2010-11.
To increase awareness of sexual transmitted infections and promote the use of condoms, we launched the Condom Essential Wear campaign in November 2006. Campaign tracking indicates that behaviour within the target audience has started to change and evidence suggests a shift in condom purchasing behaviour towards the target 18 to 24 age group.
(3) what proportion of the £26.5 million funding announced in February 2008 to improve young people's access to contraception he expects to be spent on long-acting reversible contraception; and if he will make a statement. 
Dawn Primarolo: The National Institute for Health and Clinical Excellence (NICE) published guidance on the cost-effectiveness of long-acting reversible (LARC) methods of contraception in October 2005 which found that LARC methods are more cost-effective than the combined oral contraceptive pill even at one year of use.
NICE estimated that if 7 per cent. of women switched from the contraceptive pill to LARC methods the NHS could save an estimated £100 million each year by reducing unintended pregnancies by approximately 73,000.
The national health service has been asked to prioritise improving access to LARC methods of contraception as part of their plans for the additional £26.8 million additional funding allocated in 2008-09.
Dr. Naysmith: To ask the Secretary of State for Health what measures he has in place to ensure that the £26.5 million funding announced in February 2008 to improve young people's access to contraception supports a full range of contraceptives, including long-acting reversible contraception. 
Dr. Naysmith: To ask the Secretary of State for Health (1) what records his Department holds on the proportion of primary care trusts that have undertaken a comprehensive audit of long-acting reversible contraception; 
(2) what records his Department holds on the level of GP compliance with the recommendation in Clinical Guideline CG30 that women requiring contraception should be offered a choice of all methods, including long-acting reversible contraception. 
Dawn Primarolo: Primary care trusts undertook a national baseline questionnaire of contraceptive services in 2006. The Department's document Findings of the Baseline Review of contraceptive Services (2007) has been placed in the Library.
Changes have been made to the NHS Quality and Outcomes Framework for 2009-10 for general practitioners (GPs) which include a reallocation of the points system to financially reward them for giving advice on contraception, particularly long-acting methods, to help prevent unintended pregnancies including teenage pregnancies.
John Bercow: To ask the Secretary of State for Health what discussions he has held with the National Institute for Health and Clinical Excellence on its consultation on Crohns DiseaseInfliximab (review) and Adalimumab; and when he expects it to publish its final appraisal determination. 
Dawn Primarolo: The Department had no such discussions. The National Institute for Health and Clinical Excellence (NICE) held its second appraisal committee meeting on 22 October 2008 and, subject to consideration of the comments received in response to its consultation, NICE will issue its final appraisal determination in due course.
John Bercow: To ask the Secretary of State for Health what recent estimate he has made of the annual costs to the NHS of (a) anti-TNF therapies and (b) surgery in the treatment of Crohns disease. 
Mr. Burstow: To ask the Secretary of State for Health pursuant to the answer of 4 November 2008, Official Report, columns 377-8W, on dementia: research, when he expects a complete set of dementia research expenditure data for 2007-08 to be available. 
Mike Penning: To ask the Secretary of State for Health what budget was allocated for the work of (a) Monitor, (b) the Standing Dental Advisory Committee and (c) the Doctors and Dentists Review Body in each of the last five years. 
Mike Penning: To ask the Secretary of State for Health how many paid officials work for (a) Monitor, (b) the Standing Dental Advisory Committee, (c) the Doctors and Dentists Review Body, (d) the NHS Litigation Authority, (e) the NHS Institute for Innovation and Improvement, (f) the NHS Business Services Authority and (g) the NHS Purchasing and Supply Agency. 
Keith Vaz: To ask the Secretary of State for Health what the rates of (a) type 1 and (b) type 2 diabetes were (i) in each of the last 10 years and (ii) at the most recent date for which information is available; and how often and by what mechanism the rate is measured. 
Figures for the last 10 years are not available. However, the following table shows the number of people recorded on diabetes registers (including both type one and type two diabetes) from 2004-05 to 2007-08, from the QOF. It should be noted that patients will contribute to the figures in QOF only if they are registered with a general practice participating in the QOF. QOF data are collected annually and only include people with diabetes aged 17 or over. Figures are not available broken down into type one and type two diabetes. The latest prevalence data are from June 2008.
|Patients with a recorded diagnosis of diabetes